Acute Respiratory Distress Syndrome (ARDS) Market Characteristics
The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033
The Business Research Company offers in-depth market insights through Acute Respiratory Distress Syndrome (ARDS) Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The acute respiratory distress syndrome (ards) market size has grown rapidly in recent years. It will grow from $1.17 billion in 2023 to $1.29 billion in 2024 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to advancements in critical care medicine, aging population, pulmonary rehabilitation, multidisciplinary care teams.
The acute respiratory distress syndrome (ards) market size is expected to see rapid growth in the next few years. It will grow to $1.93 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to global healthcare preparedness, vaccine development and infectious disease management, telemedicine and remote monitoring, patient-centered care models. Major trends in the forecast period include artificial lung devices, personalized ventilation strategies, lung protective ventilation, drug therapies for ards subtypes.
Get Free Sample Of This Report-
www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp
Market Segmentation:
The main types of services involved in acute respiratory distress syndrome (ARDS) are diagnosis and treatment. Diagnosis is the process of separating a disease or disorder from other potential disorders and defining its nature. The diagnosis of acute respiratory distress syndrome (ARDS) is based on the physical exam, chest X-ray and oxygen levels. It can be caused by COVID-19 disease 2019 (COVID-19), sepsis, inhalation of harmful substances, severe pneumonia and others with severity ranging from mild, moderate and severe. The major end users are hospitals, clinics, ambulatory service centers and others.
Major Driver - Impact Of Increasing Pneumonia Prevalence On The Acute Respiratory Distress Syndrome (ARDS) Market
The growing prevalence of pneumonia is expected to propel the growth of the acute respiratory distress syndrome (ARDS) market going forward. Pneumonia is an infection that affects one or both lungs, causing the lungs' air sacs, or alveoli, to fill up with fluid or pus. Pneumonia causes an inflammatory reaction in the lungs, increasing blood vessel permeability and fluid leakage into the alveoli. This fluid buildup interferes with the exchange of oxygen and carbon dioxide, causing respiratory discomfort. For instance, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2021, the number of deaths due to pneumonia in the United States was 41,309, with a mortality rate of 12.4 deaths per 100,000 population. Therefore, the growing prevalence of pneumonia drives the growth of the acute respiratory distress syndrome (ARDS) market.
Competitive Landscape:
Major players in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, ResMed Inc., Smiths Medical Inc., Dräger Safety AG & Co. KGaA., Getinge AB, Mallinckrodt PLC, Masimo Corporation, United Therapeutics Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Zuventus Healthcare Ltd., Windtree Therapeutics Inc., Faron Pharmaceuticals Oy, AcelRx Pharmaceuticals Inc.
Get Access To The Full Market Report -
www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report
Top Trend - Innovative Drug Development Initiatives Transforming The Acute Respiratory Distress Syndrome (ARDS) Market
Major companies operating in the acute respiratory distress syndrome (ARDS) market are focusing on developing innovative drugs and supplements, such as Aviptadil, HSP90 inhibitors and others to sustain their position in the market. Aviptadil is a synthesized vasoactive intestinal peptide (VIP) that binds specifically to receptors on lung alveolar type II cells. For instance, in November 2022, Zuventus Healthcare Ltd., an India-based pharmaceutical manufacturing company, launched Aviptadil to treat acute respiratory distress syndrome. Aviptadil, a vasoactive intestinal peptide supplement, improves breathing and lowers mortality in ARDS patients. This is accomplished through Aviptadil's ability to protect and regenerate Type-2 Pneumocytes, restore Type-1 Pneumocytes, increase surfactant synthesis and suppress IL-6 (interleukin 6) and tumor necrosis factor (TNF)-alpha.
The Table Of Content For The Market Report Include:
1. Executive Summary
2. Acute Respiratory Distress Syndrome (ARDS) Market Characteristics
3. Acute Respiratory Distress Syndrome (ARDS) Market Trends And Strategies
4. Acute Respiratory Distress Syndrome (ARDS) Market - Macro Economic Scenario
5. Acute Respiratory Distress Syndrome (ARDS) Market Size And Growth
…..
27. Acute Respiratory Distress Syndrome (ARDS) Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: in.linkedin.com/company/the-business-research-company
Twitter: twitter.com/tbrc_info
Facebook: www.facebook.com/TheBusinessResearchCompany
YouTube: www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: blog.tbrc.info/
Healthcare Blog: healthcareresearchreports.com/
Global Market Model: www.thebusinessresearchcompany.com/global-market-model
About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
This release was published on openPR.
